Our examination of TBX3 by immunohistochemistry in two independent patient cohorts revealed that levels are highest in hormone receptor‐positive, low‐grade DCIS (and co‐existing CCLs) and are associated with the extent of invasion in early‐stage breast cancers. Here, TBX3 is linked to breast cancer.